On November 24, 2020 Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, reported that an abstract related to its dual LSD1 and HDAC6 inhibitor, JBI-802, has been accepted for presentation at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Virtual Annual Meeting taking place Dec. 5-8, 2020 (Press release, Jubilant Therapeutics, NOV 24, 2020, View Source [SID1234571696]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to discussing our novel potent and selective dual inhibitor of LSD1-HDAC6 for the treatment of cancer at the 2020 ASH (Free ASH Whitepaper) Virtual Annual Meeting," said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics. "Our work to progress JBI-802 into the clinic as a potential, differentiated therapeutic for the treatment of select hematological and solid tumors with specific gene signatures is on track and we expect to initiate first-in-human studies in the second half of next year."

The abstract, currently available on the ASH (Free ASH Whitepaper) conference website, is as follows:

Title: Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer

Date: Monday, December 7, 2020

Session: 802. Chemical Biology and Experimental Therapeutics: Poster III

Abstract: 3378

Presenter: Dhanalakshmi Sivanandhan, Ph.D., Associate Vice President & Head of Biology, Jubilant Therapeutics Inc.